NCT02711137 2025-10-21Open-Label Safety and Tolerability Study of INCB057643 in Subjects With Advanced MalignanciesIncyte CorporationPhase 1/2 Terminated137 enrolled 31 charts
NCT02900560 2022-06-10Study of Pembrolizumab With or Without CC-486 in Patients With Platinum-resistant Ovarian CancerTranslational Research in OncologyPhase 2 Terminated34 enrolled 15 charts